SGLT2 inhibitors in patients with HFpEF: how old is too old?

Dan Tong¹

Affiliations

Comment

Dan Tong. J Cardiovasc Aging. 2022.

. 2022:2:41.

doi: 10.20517/jca.2022.30. Epub 2022 Jul 20.

Dan Tong¹

¹ Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Abstract

Conflicts of interest The author declared that there are no conflicts of interest.

Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
Böhm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, Mahfoud F, Brueckmann M, Gollop ND, Iwata T, Ponikowski P, Wanner C, Zannad F, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators. Böhm M, et al. J Am Coll Cardiol. 2022 Jul 5;80(1):1-18. doi: 10.1016/j.jacc.2022.04.040. J Am Coll Cardiol. 2022. PMID: 35772911 Clinical Trial.

1. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. - PubMed
1. Committee Members. ACC/AHA joint committee members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail 2022;28:e1–e167. - PubMed
1. Upadhya B, Pisani B, Kitzman DW. Evolution of a geriatric syndrome: pathophysiology and treatment of heart failure with preserved ejection fraction. J Am Geriatr Soc 2017;65:2431–40. - PMC - PubMed
1. Sanders NA, Supiano MA, Lewis EE, et al. The frailty syndrome and outcomes in the TOPCAT trial. Eur J Heart Fail 2018;20:1570–7. - PubMed
1. Böhm M, Butler J, Filippatos G, et al. Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age. J Am Coll Cardiol 2022;80:1–18. - PubMed